Shape Medical Systems, Inc.

Shape Medical Systems, Inc. provides predictive modeling technology to improve the early detection and therapeutic outcome assessment of heart and lung disease. The Shape technology is used to diagnose patients with heart and/or lung dysfunction or are at risk for above average future medical intervention, and to monitor the clinical outcome of standard therapy and predict future risk.

Simplifying to Improve Therapy Assessment
Shape founders realized the significant limitations of existing cardiopulmonary assessment systems and, in response, undertook to design a system that is compact, easy to use, patient friendly, provides expansive physiological data collection and interpretation, is prognostic, and can be used to frequently assess therapeutic response. The Shape-HF™ Cardiopulmonary Exercise Testing System is the culmination of years of research effort dedicated to this effort.

Monitoring Chronic Disease
Shape technology has application with more than 100 million Americans, with patient populations found in Europe and Asia. The Company's core strategy is driven by the growing need to determine the cardiopulmonary risk of an aging population, to identify those people with greater than average risk of disease progression, and to monitor pre-treatment or treatment results. This strategy goes directly to assessing the risk of developing chronic disease, thereby giving healthcare providers options for early stage therapeutic intervention to control disease progression, or to monitor those patients suffering chronic conditions over the longer term.

Shape Medical Systems is developing technology that transcends the spectrum from pre-disease risk assessment, to disease stratification, to clinical outcome following intervention. Our focus is on chronic disease, prevention, and therapeutic assessment affecting major segments of the global population.